Tricida, Inc. (TCDA) |
| 0.108 0 (0%) 01-23 16:00 |
| Open: | 0.1156 |
| High: | 0.116 |
| Low: | 0.0925 |
| Volume: | 31,125,310 |
| Market Cap: | 6(M) |
| PE Ratio: | -0.02 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 13.85 |
| 52w Low: | 0.0411 |
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Tue, 01 Jul 2025
Claim form open in Tricida Inc. $14.25M securities settlement - Claim Depot
Wed, 18 Jan 2023
Tricida Stock Rallied 39% on Short Squeeze After Bankruptcy Filing - AskTraders
Thu, 03 Nov 2022
Peninsula kidney drug company weighs 'strategic alternatives' after clinical trial flop - The Business Journals
Mon, 24 Oct 2022
Tricida Shares Plunge 94% After Kidney Disease Drug Fails Trial - Barron's
Mon, 24 Oct 2022
Tricida Stock Crashed 94%, Trial Failed To Meet Primary Endpoints - AskTraders
Tue, 29 Mar 2022
Tricida Announces Fourth Quarter and Full Year 2021 Financial Results - GlobeNewswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
